Latest News about INCY
Recent news which mentions INCY
From Benzinga
From Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
Tags
NASDAQ:BGNE,NASDAQ:INCY,NASDAQ:BMRN,NASDAQ:ARGX,NASDAQ:UTHR,NASDAQ:TECH,NASDAQ:LEGN
BMRN
Market News
From InvestorPlace
Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target
April 10, 2023
Tickers
INCY
From Benzinga
From Benzinga
From Benzinga
Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact'
March 24, 2023
Tickers
INCY
From Benzinga
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
March 23, 2023
From Benzinga
From InvestorPlace
Why Shares of MacroGenics Climbed Thursday
March 16, 2023
From Motley Fool
Incyte Discontinues LIMBER-304 On Doubts Regarding Meeting Primary Goal, Analyst Says It Underpins Some Investor Concerns
March 06, 2023
Tickers
INCY
From Benzinga
Why the stock market rally can keep going, says Wall Street strategist who only recently warned of a death zone.
March 06, 2023
From MarketWatch
2 Steady Stocks to Buy in a Recession
February 03, 2023
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
January 31, 2023
From Benzinga
7 Biotech Stocks That Will Make You Rich in 10 Years
January 18, 2023
From InvestorPlace
Why These 7 Healthcare Stocks Could Soar in 2023
January 02, 2023
From InvestorPlace
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
December 29, 2022
From Motley Fool
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
December 18, 2022
From InvestorPlace
Cramer Says He's 'Always Liked' This Drug Company
December 16, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.